Vice President, Strategy & Business Development - Advanced Therapeutics Division

Agilent Technologies•Boston, MA

3d•Remote

About The Position

Agilent is seeking an enterprise leader for its Advanced Therapeutics Division (ATD), a specialty CDMO platform spanning RNA oligonucleotide manufacturing in Colorado and BioVectra in Canada. The approximately $600 million business serves pharmaceutical and biotechnology customers from early development through commercial-scale manufacturing and is a significant growth platform for LDG. The Vice President, Strategy and Business Development is an enterprise executive role responsible for the division’s growth, performance and strategic development. The role spans commercial growth, portfolio and technology strategy, early R&D, strategic marketing, customer alliances, capital allocation and M&A. The leader will shape the division’s competitive focus, develop a predictable revenue pipeline, allocate resources to attractive opportunities, and build an integrated organization capable of sustained, profitable growth. The role connects strategy and customer commitments to capacity, technical delivery, quality and economics. The position owns the ATD P&L and overall performance, and leads global business development, strategic customer relationships, portfolio and innovation priorities, capital allocation and inorganic growth opportunities. It also leads a geographically distributed, cross-functional organization across portfolio strategy, business development, early R&D, marketing and support functions, while aligning closely with operations and enterprise partners. The role is based in Santa Clara, California, with additional Agilent sites and remote work considered. Occasional travel is required. The full-time equivalent pay range is $280,000–$481,250 per year, with eligibility for bonus, stock and benefits.

Requirements

At least 15 years of progressive leadership experience in CDMO, biopharma manufacturing, life-sciences tools or services, or a closely related sector, including significant executive responsibility.
Demonstrated accountability for commercial growth and meaningful financial outcomes at scale.
Broad understanding of pharmaceutical and biotechnology customers and the scientific, regulatory, quality and economic dynamics of development and manufacturing.
Experience in business development, strategic-account leadership, and creating and converting complex, high-value revenue pipelines.
Meaningful leadership across portfolio strategy, strategic marketing, early R&D or technology choices, with a record of translating market insight into investment priorities.
Operational fluency and credibility, including understanding capacity, technical transfer, program delivery, quality, productivity and capital tradeoffs.
Direct experience with major organic capital decisions and meaningful involvement in M&A, partnerships, diligence and integration.
Ability to integrate resources across a large global matrix and influence executive stakeholders who are not direct reports.
Bachelor’s degree in a relevant scientific, engineering or business discipline.
Enterprise-minded and accountable leadership, with the ability to set direction, make choices and own commercial and financial outcomes.
Commercial and strategic sophistication, including the ability to connect differentiated capabilities to customer and enterprise value.
Decisiveness and resilience in response to changing customer programs, market shifts and execution challenges.
Collaborative and influential approach to building trust and alignment across organizational boundaries.
Data- and process-oriented approach using meaningful KPIs and operating mechanisms to improve decision quality, predictability and accountability.
Ability to develop leaders, communicate complex strategy clearly and build talent and succession depth.

Nice To Haves

Full P&L ownership; comparable responsibility for a major business, portfolio, commercial function or growth agenda will also be considered.
Relevant exposure to nucleic-acid therapeutics, oligonucleotides, RNA, biologics, APIs, peptides, complex chemistry or other advanced therapeutic modalities.
Direct oligonucleotide experience is highly desirable.
An advanced scientific, engineering or business degree.

Responsibilities

Own the full P&L and overall ATD performance, including revenue growth, profitability, margin expansion, cash generation and return on invested capital.
Set and evolve the multiyear growth agenda, translating strategy into operating priorities, resource choices and measurable outcomes.
Establish a data- and KPI-based operating cadence across the commercial pipeline, program execution, productivity, innovation, quality and financial performance.
Own global business-development strategy and the revenue pipeline from market development and lead generation through qualification, contracting, program award, scale-up and commercial handoff.
Build a systematic commercial engine that improves pipeline quality, deal velocity, conversion, forecast accuracy and strategic-account expansion.
Develop relationships with senior pharmaceutical and biotechnology decision makers, lead consequential opportunities, and align customer commitments with capabilities, capacity, quality, capital needs and long-term economics.
Build alliances with customers, technology partners and platform collaborators, and represent Agilent at customer engagements, industry forums and scientific conferences.
Translate external customer, scientific and market insight into portfolio, R&D and investment decisions.
Define portfolio strategy across RNA oligonucleotides, BioVectra and relevant adjacent modalities, identifying differentiated and defensible market positions.
Oversee early-stage R&D and technology investment priorities, aligning innovation with customer problems and commercially attractive emerging modalities.
Lead strategic marketing, segmentation, positioning and market development; assess modality mix, service-line expansion, capacity needs and technology evolution.
Drive strategic capital allocation across manufacturing capacity, technology platforms, R&D and commercial capabilities in collaboration with Global Operations.
Identify and develop acquisitions, partnerships, licensing opportunities and other strategic investments; build business cases and secure alignment with Agilent leadership, Finance and Corporate Development.
Co-lead strategic and organizational integration of acquired businesses and capabilities, with accountability for realizing growth and value-creation objectives.
Lead and develop a geographically distributed, cross-functional organization spanning portfolio strategy, business development, early R&D, marketing and support functions.
Integrate the Colorado and BioVectra businesses while preserving speed, expertise and customer responsiveness.
Build alignment across the global matrix and partner with Operations, Quality, Regulatory, Finance, HR, Legal, Corporate Development and other enterprise functions.
Attract and develop talent, build succession depth, and foster customer focus, accountability, collaboration, scientific curiosity and continuous improvement.